Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.68 |
| ▸ | CCNT1 | O60563 | 2/20 | 0.39 |
| ▸ | CDK9 | P50750 | 2/20 | 0.39 |
| ▸ | PNP | P00491 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.37 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.37 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.36 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7215122 | 1.00 | HDAC6 (0.68) | HDAC6CCNT1CDK9PNPLMNA | |
| SCHEMBL7209010 | 1.00 | HDAC6 (0.68) | HDAC6CCNT1CDK9PNPLMNA | |
| SCHEMBL7209018 | 1.00 | HDAC6 (0.68) | HDAC6CCNT1CDK9PNPLMNA | |
| SCHEMBL7215077 | 0.82 | HDAC6 (0.69) | HDAC6CCNT1CDK9 | |
| SCHEMBL7215079 | 0.82 | HDAC6 (0.69) | HDAC6CCNT1CDK9 | |
| SCHEMBL17864244 | 0.82 | HDAC6 (0.69) | HDAC6CCNT1CDK9 | |
| Maribavir SCHEMBL7634766 | 0.81 | HDAC6 (1.00) | HDAC6LMNASMN1; SMN2RXFP1 | |
| Maribavir SCHEMBL18459197 | 0.81 | HDAC6 (1.00) | HDAC6LMNASMN1; SMN2RXFP1 | |
| Maribavir SCHEMBL1028527 | 0.81 | HDAC6 (1.00) | HDAC6LMNASMN1; SMN2RXFP1 | |
| Maribavir SCHEMBL13082009 | 0.81 | HDAC6 (1.00) | HDAC6LMNASMN1; SMN2RXFP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160175338-A1 | MARIBAVIR ISOMERS, COMPOSITIONS, METHODS OF MAKING AND METHODS OF USING | VIROPHARMA INCORPORATED | 2016-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160175338-A1 | MARIBAVIR ISOMERS, COMPOSITIONS, METHODS OF MAKING AND METHODS OF USING | POLB, CYP4B1, CYP3A4 | HDAC6 2079/4885CCNT1 357/4885CDK9 223/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.